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Abstract
Introduction: Synovial tissue macrophages play a key role in chronic inflammatory arthritis, but the contribution of
different macrophage subsets in this process remains largely unknown. The main in vitro polarized macrophage
subsets are classically (M1) and alternatively (M2) activated macrophages, the latter comprising interleukin (IL)-4 and
IL-10 polarized cells. Here, we aimed to evaluate the polarization status of synovial macrophages in
spondyloarthritis (SpA) and rheumatoid arthritis (RA).
Methods: Expression of polarization markers on synovial macrophages, peripheral blood monocytes, and in vitro
polarized monocyte-derived macrophages from SpA versus RA patients was assessed by immunohistochemistry
and flow cytometry, respectively. The polarization status of the intimal lining layer and the synovial sublining
macrophages was assessed by double immunofluorescence staining.
Results: The expression of the IL-10 polarization marker cluster of differentiation 163 (CD163) was increased in SpA
compared with RA intimal lining layer, but no differences were found in other M1 and M2 markers between the
diseases. Furthermore, no significant phenotypic differences in monocytes and in vitro polarized monocyte-derived
macrophages were seen between SpA, RA, and healthy controls, indicating that the differential CD163 expression
does not reflect a preferential M2 polarization in SpA. More detailed analysis of intimal lining layer macrophages
revealed a strong co-expression of the IL-10 polarization markers CD163 and cluster of differentiation 32 (CD32) but
not any of the other markers in both SpA and RA. In contrast, synovial sublining macrophages had a more
heterogeneous phenotype, with a majority of cells co-expressing M1 and M2 markers.
Conclusions: The intimal lining layer but not synovial sublining macrophages display an IL-10 polarized-like
phenotype, with increased CD163 expression in SpA versus RA synovitis. These differences in the distribution of the
polarized macrophage subset may contribute to the outcome of chronic synovitis.
Introduction
The normal synovial membrane consists of two distinct
structures: the intimal lining layer and the synovial sub-
lining. The normal intimal lining layer comprises fibro-
blast-like synoviocytes and intimal lining layer
macrophages, whereas the synovial sublining consists of
connective tissue containing blood vessels, fibroblasts,
adipocytes, and a limited number of resident immune
cells, such as macrophages and mast cells [1]. Chronic
inflammatory arthritis is histologically characterized by
marked hyperplasia of the intimal lining layer and mas-
sive infiltration of the synovial sublining with innate and
adaptive immune cells, which release inflammatory med-
iators, promote neoangiogenesis, and drive the destruc-
tion of adjacent cartilage and bone [2]. Macrophages
play a major role in this process because they contribute
to the intimal lining layer hyperplasia [3] and are the
main producers of key inflammatory mediators, such as
tumor necrosis factor (TNF) [4]. Accordingly, the num-
ber of synovial macrophages correlates with clinical dis-
ease activity [2,5] and decreases after clinically efficient
but not placebo treatment in both rheumatoid arthritis
(RA) [6-9] and spondyloarthritis (SpA) [10-13].
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Furthermore, selective macrophage depletion has a
strong antiinflammatory effect in animal models of
arthritis [14].
Tissue macrophages consist of resident macrophages
and monocytes that are recruited in inflammatory con-
ditions and differentiate into macrophages on tissue
entry. These macrophages represent a heterogeneous
population, as local mediators can prime macrophages
during their maturation and thereby shape their subse-
quent response to various activating stimuli [15,16].
Initially, two main polarized macrophage subsets were
described based on their pro- versus antiinflammatory
functions: classically activated macrophages (M1), which
are specialized in the clearance of intracellular patho-
gens, and alternatively activated macrophages (M2),
which have immunoregulatory properties and are
involved in scavenging debris, angiogenesis, and tissue
repair [17]. The M1 subset is induced mainly by inter-
feron (IFN)-g (MFIFN-g), whereas M2 can be induced in
vitro either by IL-4 (MFIL-4)/IL-13 or by IL-10 (MFIL-
10) [17-20]. Whereas the macrophage polarization has
been best described in rodents, we recently validated
specific phenotypic markers [21] and distinct functional
characteristics (unpublished observations) for these
three main in vitro polarized macrophage subsets in
humans.
The increasing knowledge of the phenotypic and func-
tional diversity of human macrophages indicates that
not only the overall number of macrophages in the
inflamed tissue, but also their specific polarization status
may determine the disease outcome in terms of severity,
chronicity, and tissue damage. Interestingly, we pre-
viously described that, despite similar numbers of
macrophages in RA and SpA synovitis, a selective over-
representation of CD163+ macrophages was present in
SpA [3,22-25]. CD163, the scavenger receptor for hemo-
globin/haptoglobin complexes, is a known marker for
IL-10 or M-CSF polarized M2 [21,26]. Together with
the lower levels of M1-derived proinflammatory cyto-
kines in SpA versus RA synovial fluid [27] and the
defective IFN-g signature in SpA monocytes [28], these
data suggest a preferential M2 polarization in SpA com-
pared with an M1 polarization in RA. The aim of this
study was to test this hypothesis by detailed characteri-




Peripheral blood samples were obtained from 11 SpA
and eight RA patients and nine healthy controls. Syno-
vial biopsies were obtained with small-bore arthro-
scopy from clinically inflamed knee joints, as
previously described [29], and 18 SpA and 20 RA
patients were included for the immunohistochemical
analysis. All SpA patients fulfilled the criteria of the
European Spondyloarthropathy Study Group (ESSG)
[30], and all RA patients fulfilled the 1987 ACR classi-
fication criteria for RA [31]. Demographic and clinical
data of the patients are shown in Table 1. None of the
patients was being treated with biologicals. All patients
gave written informed consent to participate to the
study, as approved by the Medical Ethics Committee
of the Academic Medical Centre/University of
Amsterdam.
Immunohistochemistry
Synovial biopsy samples (six to eight per patient to
minimize sampling error) were snap-frozen en bloc and
mounted in Jung tissue-freezing medium (Leica Instru-
ments, Nussloch, Germany). The acetone-fixed sections
were stained by using mouse monoclonal antibodies
directed toward CD68 (clone EBM-11; Dako, Heverlee,
The Netherlands), CD64 (clone 10.1; BioLegend,
Uithoorn, The Netherlands), CD14 (clone TUK4; Dako),
CD163 (clone 5cFAT; BMA Biomedicals, Augst, Swit-
zerland), and CD32 (clone AT10; abcam, Cambridge,
UK). Sections were sequentially incubated with a bioti-
nylated secondary antibody, a streptavidin-horseradish
peroxidase link (LSAB; Dako), aminoethylcarbazole sub-
strate as chromogen, and hematoxylin as counterstain
[22,25]. Parallel sections were incubated with isotype-
and concentration-matched monoclonal antibodies as
negative controls. The expression of CD200R was
assessed with immunofluorescence, by using a mouse
monoclonal antibody (clone OX108; AbD Serotec, Düs-
seldorf, Germany). For each cohort, samples were
stained in a single run, coded, and scored in a random
order on a 4-point semiquantitative scale by two
Table 1 Demographic and clinical features of the patients
in the two cohorts









Gender, % female 40 58 33 100
Age, years 47 (33-55) 62 (53-74) 38 (31-44) 48 (32-63)
Disease duration, years 3 (1-29) 3 (1-11) 2 (1-4) 2 (1-5)
Swollen-joint count 1 (1-2) 8 (5-15) 1 (0-1) 1 (0-2)
CRP, mg/L 12 (5-31) 19 (8-58) 2 (1-7) 5 (4-11)
ESR, mm/hour 29 (23-43) 47 (33-66) 2 (2-16) 21 (13-29)
% using DMARDs 80 54 50 100
As described in Materials and methods, synovial tissue biopsies were obtained
from patients with spondyloarthritis (SpA) and rheumatoid arthritis (RA)
(Cohort 1). Monocytes were isolated from peripheral blood of SpA and RA
patients (Cohort 2). Except when indicated otherwise, values are expressed as
the median (interquartile range). CRP, C-reactive protein; DMARD, disease-
modifying anti-rheumatic drug; ESR, erythrocyte sedimentation rate.
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independent observers (CAA, TN), as described pre-
viously [5].
Monocyte isolation and in vitro polarization
Monocytes were isolated from peripheral blood with
gradient centrifugation with Lymphoprep (Axis-Shield
PoPAS, Oslo, Norway) and, subsequently, Percoll gradi-
ent separation (GE Healthcare, Uppsala, Sweden).
Monocytes were analyzed immediately with flow cyto-
metry or cultured at a concentration of 0.5 × 106/ml in
Iscove Modified Dulbecco Medium (IMDM) (Invitrogen,
Breda, The Netherlands) supplemented with 10% fetal
calf serum (FCS) (PAA Laboratories, Cölbe, Germany).
Cultured monocytes were polarized in vitro with human
recombinant IFN-g (10 ng/ml; R&D Systems, Abingdon,
UK), IL-4 (10 ng/ml; Miltenyi Biotec, Bergisch Glad-
bach, Germany), or IL-10 (10 ng/ml; R&D Systems) for
4 days. For further analysis, polarized macrophages were
recovered by scraping of the culture plate.
Flow cytometry
Surface-marker expression on monocytes and in vitro
polarized macrophages was analyzed with flow cytome-
try (BD FACS Calibur Flow Cytometer, Erembodegem,
Belgium) by using fluorochrome-labeled monoclonal
antibodies against CD80 (clone L307.4; BD Pharmingen,
Breda, the Netherlands), CD64 (clone 10.1; BioLegend),
CD200R (clone OX108; AbD Serotec), CD14 (clone
61D3; eBioscience, San Diego, CA, USA), CD163 (clone
GHI/61; BD Pharmingen), and CD16 (clone DJ130c;
AbD Serotec, Düsseldorf, Germany). Equivalent amounts
of isotype-matched control antibodies were included in
all experiments as negative controls. Before staining, Fc
receptors were blocked with 10% human serum (Lonza,
Cologne, Germany). Data were analyzed with Flow Jo
Flow Cytometry Analysis software (Tree Star, Ashland,
OR, USA) after gating on the myeloid population in the
FSC/SSC window. Values were expressed as the ratio of
the geometric mean fluorescence intensity (gMFI) of the
marker of interest over the gMFI of the isotype control.
Double immunofluorescence
Frozen synovial tissue sections were fixed in acetone
and blocked with 10% goat serum (Dako, Glostrup, Den-
mark), followed by incubation with Biotin blocking sys-
tem (Dako). Mouse monoclonal antibodies against
CD80 (clone 2D10; BioLegend, Uithoorn, The Nether-
lands), CD64 (clone 10.1; BioLegend), CD200R (clone
OX108; AbD Serotec, Düsseldorf, Germany), CD14
(clone TUK4; Dako), CD163 (clone 5cFAT; BMA Bio-
medicals, Augst, Switzerland), CD16 (clone HI16a;
Abbiotec, San Diego, CA, USA), and CD32 (clone
AT10; abcam, Cambridge, UK) were added, followed by
incubation with Alexa-555-conjugated goat anti-mouse
antibody (Molecular Probes Europe, Leiden, The Neth-
erlands). After blocking with 10% mouse serum (Dako),
the sections were incubated with biotinylated mouse
monoclonal antibodies against CD68 (clone Y1/82A;
BioLegend), CD64 (clone 10.1; BioLegend), CD200R
(clone OX108; AbD Serotec), and CD163 (clone GHI/
61; BioLegend). After incubation with streptavidin-Alexa
488 (Molecular Probes Europe, Leiden, The Nether-
lands), the slides were mounted with Vectashield con-
taining DAPI (Vector Laboratories, Burlingame, CA,
USA) and analyzed on a fluorescent imaging microscope
(Leica DMRA, Wetzlar, Germany) coupled to a charge-
coupled device (CCD) camera and Image-Pro Plus soft-
ware (Media Cybernetics, Dutch Vision Components,
Breda, The Netherlands). To quantify the coexpression
of CD68 with CD64, CD200R, CD14, and CD163, the
number of positively stained cells was counted in a
minimum of five microscopic fields, and the percentage
of double-positive cells from the total number of CD68-
positive cells was calculated.
Statistics
Statistical analysis was performed by using Prism soft-
ware (GraphPad, La Jolla, CA, USA). Data were
expressed as median ± interquartile range. A Mann-
Whitney test was used for comparisons between two
groups (SpA compared with RA) and ANOVA followed
by a Bonferroni posttest was used for comparisons
among more than two groups. A P value of less than
0.05 was considered statistically significant.
Results
The expression of CD163 but not other M2 phenotypic
markers is increased on intimal lining layer macrophages
in SpA versus RA synovitis
To confirm and extend our previous description of
increased CD163 expression in SpA compared with RA
synovitis [3,22-25], we performed a detailed histologic
analysis of the recently described panel of phenotypic
markers for MFIFN-g, MFIL-4, and MFIL-10 [21]. As pre-
viously shown, the number of CD68+ macrophages in
the intimal lining layer and synovial sublining was simi-
lar between the two diseases (Figure 1A, D), whereas
CD163 expression was higher in the SpA compared
with the RA intimal lining layer (P < 0.05) (Figure 1B),
but similar in the synovial sublining (Figure 1E). How-
ever, the expression of another MFIL-10 marker, CD32,
was similar in both diseases, for both the intimal lining
layer and the synovial sublining (Figure 1C, F). The
expression of the MFIFN-g marker CD64, the positive
MFIL-4 marker CD200R, and the negative MFIL-4 mar-
ker CD14 was similar in the synovial sublining of SpA
and RA (Figure 1G through 1I) and was very low to
absent in the intimal lining layer (data not shown).
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These histologic data confirmed the higher CD163
expression in SpA compared with RA synovitis, but
failed to provide additional evidence for a biased M2
polarization in SpA.
The phenotype of peripheral blood monocytes is similar
in SpA and RA
To investigate whether the increased expression of
CD163 in SpA synovitis is related to preferential MFIL-
10 polarization, we set up a series of additional experi-
ments. Because monocytes from peripheral blood of
SpA patients display a defective IFN-g signature [28]
and IFN-g is the prototypic M1 polarizing cytokine, we
first assessed whether not only intimal lining layer
macrophages, but also peripheral blood monocytes have
a distinct phenotype in SpA. We quantified the
percentage of classic CD14+CD16- monocytes, inter-
mediate CD14+CD16+ monocytes, and nonclassic
CD14dimCD16+ monocytes [32] in peripheral blood
from SpA and RA patients and healthy donors, and did
not observe differences in these monocyte subsets
between the groups (Figure 2A). We next assessed the
expression of macrophage polarization markers on
CD14+ monocytes and measured a marked expression
of the MFIFN-g marker CD64 and a more modest
expression of the MFIL-4 marker CD200R and the
MFIL-10 marker CD16 (Figure 2B-D). However, no dif-
ferences were found in the expression of these markers
between SpA and RA patients and healthy controls.
Expression of MFIFN-g marker CD80 and MFIL-10 mar-
ker CD163 on monocytes was very low (data not
shown). Based on this assessment, no indication exists
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Figure 1 Immunohistochemical analysis of the expression of polarization markers in spondyloarthritis (SpA) compared with
rheumatoid arthritis (RA) synovial tissue. The expression of CD68, CD163, and CD32 in the intimal lining layer (A through C) and the
expression of CD68, CD64, CD200R, CD14, CD163 and CD32 in the synovial sublining (D through I) as assessed with semiquantitative scoring (0
to 3) of immunohistochemical stainings. Data are represented as median and interquartile range of 18 SpA and 20 RA patients.
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of phenotypic differences between monocytes from SpA
and RA patients and healthy individuals.
The phenotype of in vitro polarized monocyte-derived
macrophages is similar in SpA and RA
Further to investigate the propensity of monocytes to
polarize preferentially toward a specific macrophage
subset in SpA, monocytes from SpA and RA patients
and healthy donors were polarized in vitro in the pre-
sence of IFN-g, IL-4, or IL-10. The expression of specific
phenotypic markers was measured with flow cytometry
after 4 days of polarization. On spontaneous macro-
phage maturation in the absence of polarizing cytokines,
no differences were noted in the expression of phenoty-
pic markers between SpA and RA patients and healthy
donors (data not shown). As previously described in
healthy donors [21], IFN-g specifically upregulated the
membrane expression of CD80 and CD64, IL-4 upregu-
lated CD200R and downregulated CD14, whereas IL-10
upregulated CD163 and CD16. After polarization of
patient and healthy donor monocytes, we measured a
similar modulation of these phenotypic markers in all
three groups (Figure 3). In conclusion, we found no evi-
dence for differences in the polarization potential of
monocyte-derived macrophages from SpA and RA
patients and healthy individuals.
Intimal lining layer macrophages display a MFIL-10-like
phenotype
Because we observed an increased expression of CD163,
but no differences in the expression of other polariza-
tion markers in SpA compared with RA synovitis, we
next performed double-immunofluorescence staining to
characterize further the polarization phenotype of syno-
vial macrophages. We studied the colocalization of pan-
macrophage marker CD68 with MFIFN-g marker CD64
(Figure 4A), MFIL-4 markers CD200R and CD14 (Figure
4B, C), and MFIL-10 markers CD163, CD16, and CD32
(Figure 4D-F). Intimal lining layer CD68+ cells highly
expressed the MFIL-10 markers CD163 and CD32 (Fig-
ure 4D, F), whereas the expression of CD64, CD80,




















































Figure 2 Monocyte subsets and expression of phenotypic markers on spondyloarthritis (SpA) and rheumatoid arthritis (RA) patients
and healthy donor monocytes. The percentage of CD14+CD16-, CD14+CD16+, and CD14dimCD16+ monocytes from SpA and RA patients and
healthy donors was measured with flow cytometry (A). Expression of CD64, CD200R, and CD16 on monocytes from SpA and RA patients and
healthy donors was measured with flow cytometry and expressed as geometric mean fluorescence intensity (gMFI). Data are represented as
median and interquartile range of at least seven independent experiments (B).
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Figure 3 Expression of phenotypic markers on in vitro polarized monocyte-derived macrophages from spondyloarthritis (SpA) and
rheumatoid arthritis (RA) patients and healthy individuals. The expression of MFIFN-g markers CD80 and CD64, MFIL-4 markers CD200R and
CD14, and MFIL-10 markers CD163 and CD16 was measured with flow cytometry on in vitro polarized monocyte-derived macrophages. Data are
expressed as geometric mean fluorescence intensity (gMFI) of the marker expression after polarization with IFN-g, IL-4, or IL-10, respectively,
divided by the gMFI of the marker expression on unpolarized macrophages. Data are represented as median and interquartile range of at least
five independent experiments.
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4A-C, 4E) in both SpA and RA. In contrast, synovial
sublining macrophages abundantly expressed both the
MFIL-10 markers CD163 and CD32 (Figure 4D, F) and
the MFIFN-g marker CD64 (Figure 4A). The positive
MFIL-4 marker CD200R showed a low expression and
low colocalization with CD68 (Figure 4B), whereas the
negative MFIL-4 marker CD14 strongly colocalized with
CD68 (Figure 4C). In agreement with previous reports,
CD80 expression was almost absent in synovial tissue
(data not shown) [33], whereas CD16 expression was
low on CD68+ cells (Figure 4E). Although the number
of samples used in these double-immunofluorescence
experiments is too small for an accurate statistical analy-
sis, quantification of the staining confirmed the lack of
marked differences in the expression of these markers
between SpA and RA synovial sublining macrophages
(Figure 5). These findings suggest an MFIL-10-like phe-
notype of intimal lining layer macrophages in both SpA
and RA, whereas synovial sublining macrophages had a
more heterogeneous phenotype.
CD68 CD163 DAPI CD68 CD16 DAPI CD68 CD32 DAPI 
CD68 CD64 DAPI CD68 CD14 DAPI CD68 CD200R DAPI 
A B C 
D E F 
Figure 4 Double immunofluorescence stainings of CD68 and macrophage polarization markers on synovial tissue from chronic
inflammatory arthritis. Colocalization of CD68 (green) with MFIFN-g marker CD64 (A), MFIL-4 markers CD200R (B) and CD14 (C), and MFIL-10
markers CD163 (D), CD16 (E), and CD32 (F) (red) on synovial tissue macrophages. Figures are representative of five spondyloarthritis (SpA) and
five rheumatoid arthritis (RA) patients. Higher-magnification photos are included in each figure part.
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Synovial sublining macrophages co-express MFINF-g and
MFIL-10 markers
To characterize further the phenotype of synovial sub-
lining macrophages, we studied the colocalization of
MFIFN-g marker CD64 with CD200R, CD163, and CD32
(Figure 6A-C), colocalization of MFIL-4 marker CD200R
with CD14, CD163, and CD32 (Figure 6D-F), and colo-
calization of MFIL-10 marker CD163 with CD14 and
CD32 (Figure 6G, H). These stainings confirmed that
both MFIL-10 markers CD163 and CD32 were expressed
on the same cells in SpA and RA synovitis (Figure 6H).
However, we also observed a high degree of coexpres-
sion between the MFINF-g marker CD64 and the MFIL-
10 markers CD163 and CD32 (Figure 6B, C). Further-
more, the smaller macrophage subset that expressed the
MFIL-4 marker CD200R also appeared to coexpress
CD64, CD14, CD163, and CD32 (Figure 6D-F). Taken
together, these data indicate that synovial sublining
macrophages display a mixed MFINF-g/MFIL-10 pheno-
type. Within this population, a smaller macrophage sub-
set also coexpresses the MFIL-4 marker CD200R.
Discussion
Synovial tissue macrophages play a key role in chronic
inflammatory arthritis, but the distribution and the





































































Figure 5 Expression of polarization markers on CD68+ cells in synovial tissue from chronic inflammatory arthritis. Figure represents the
percentage of CD64+ (A), CD200R+ (B), CD14+ (C), and CD163+ (D) cells from the total number of CD68+ cells in five spondyloarthritis (SpA)
and five rheumatoid arthritis (RA) patients. Data were acquired by manual quantitative scoring of double-immunofluorescence stainings and are
represented as median and interquartile range.
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CD163 CD32 DAPI 
H 
CD64 CD163 DAPI 
B 
CD64 CD32 DAPI 
C 
CD64 CD200R DAPI 
A 
F 
CD200R CD32 DAPI CD200R CD163 DAPI 
E 
CD163 CD14 DAPI 
CD200R CD14 DAPI 
D 
G 
Figure 6 Double-immunofluorescence stainings of MFIFN-g, MFIL-4, and MFIL-10 polarization markers on synovial tissue from chronic
inflammatory arthritis. Colocalization of MFIFN-g marker CD64 with CD200R (A), CD163 (B), and CD32 (C), colocalization of MFIL-4 marker
CD200R with CD14 (D), CD163 (E), and CD32 (F), and colocalization of MFIL-10 marker CD163 with CD14 (G) and CD32 (H). Figure parts are
representative of five spondyloarthritis (SpA) and five rheumatoid arthritis (RA) patients.
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remain largely unknown. Based on the increased CD163
expression in SpA synovitis [3,22-25], we proposed the
hypothesis of a preferential M2 polarization in SpA, as
opposed to an M1 polarization in RA [27]. The present
study aimed to assess this hypothesis experimentally by
a detailed characterization of macrophages in inflamma-
tory arthritis, by using a recently validated panel of phe-
notypic markers for in vitro polarized human
macrophage subsets [21]. Comparison of macrophage
phenotypic marker expression between SpA and RA
synovitis confirmed the higher expression of CD163 in
the SpA intimal lining layer. Although previous reports
showed increased CD163 expression in both the intimal
lining layer and synovial sublining, the differences
appeared to be larger in the intimal lining layer [3,22].
As CD163 is a prototypical marker for MFIL-10, we
performed three types of experiments to assess whether
the increased CD163 expression reflected a preferential
M2 polarization in SpA. First, the previously described
inverse IFN-g signature in monocytes from SpA patients
[28] suggested that even before entering the synovial
compartment, myeloid cells may be skewed to polarize
toward M2 rather than M1. Our analysis of peripheral
blood monocytes, however, did not reveal phenotypic
differences between SpA, RA, and healthy controls. In
humans, three monocyte subsets have been identified:
classic CD14+CD16-, intermediate CD14+CD16+, and
nonclassic CD14dimCD16+ monocytes. Among these
subsets, CD14+CD16+ monocytes were described to be
recruited in tissues during inflammation and to produce
high amounts of TNF [32,34-37]. Although other publi-
cations report contrasting findings of either an increased
[38-40] or a decreased [41] percentage of CD14+CD16+
monocytes in inflammatory compared with healthy con-
ditions, our experiments did not identify differences in
these monocyte subsets between SpA and RA patients
and healthy donors. Additionally, we did not observe
differential expression of other phenotypic markers,
such as CD64, CD16, and CD32, whereas the expression
of CD80 and CD163 was very low on peripheral mono-
cytes, as previously described [42,43].
Second, we assessed whether a potential bias toward
M2 may appear during the differentiation of monocytes
toward macrophages. In vitro polarization experiments
with monocyte-derived macrophages failed, however, to
indicate preferential polarization to a distinct subset in
SpA compared with RA patients and healthy donors.
These data suggest that the CD163+ macrophage pheno-
type in SpA synovitis is determined by the local inflam-
matory milieu rather than by intrinsic myeloid
alterations. Previous publications showing CD163 upre-
gulation during in vitro macrophage maturation in the
presence of SpA synovial fluid [27] and a strong synovial
CD163 downregulation on effective antiinflammatory
treatment [12,13] support this observation.
Third, we assessed whether the local upregulation of
CD163 on intimal lining layer macrophages in SpA was
associated with differential expression of other phenoty-
pic polarization markers between SpA and RA. This
was not the case, as, for example, both the MFIL-10
marker CD32 and the prototypical MFIFN-g marker
CD64 were similarly expressed in both diseases. These
data question whether the altered expression of CD163,
which is a reliable M2 marker in vitro, necessarily
reflects a marked M2 versus M1 polarization in vivo.
Supporting the notion that the phenotype of macro-
phage subsets in vivo is more complex than the concep-
tual in vitro framework of M1 and M2, detailed double-
staining analysis showed that synovial sublining macro-
phages display a mixed phenotypic profile with a high
colocalization of MFIFN-g and MFIL-10 markers. Similar
observations of mixed polarization profiles were already
described for human adipose tissue macrophages
(ATMs), which show features of both alternative
(CD206, CD163, IL-10, TGF-b) and classic (TNF, IL-6,
IL-23, IL-8) activation [44,45]. An important question
raised by this in vivo complexity is whether these cells
exert both the pro- and antiinflammatory functions,
which have been attributed to M1 and M2 macro-
phages, respectively, or whether they are steady-state
cells waiting for additional signals to determine their
ultimate phenotype and function. The latter hypothesis
implies a large plasticity of tissue macrophages, as pre-
viously suggested in tumor environment [46], adipose
tissue [47], and atherosclerosis [48]. Tumor-associated
macrophages were described to have M2 properties,
with low inflammatory chemokine receptors, poor anti-
gen presentation, high IL-10, and low IL-12 production
[49-53]. Interestingly, polarization toward an M1-like
phenotype was shown to suppress tumor progression
[54]. Adipose tissue macrophages were also reported to
switch from an M2-like phenotype in normal adipose
tissue to an M1-like phenotype in diet-induced obesity
[55,56], but reports exist of a predominant M2 activa-
tion in insulin resistance and obesity [57]. The same
holds true for the macrophages in the vascular wall,
which were described to switch from an M2- to an M1-
like phenotype and become so-called foam cells [58-60],
whereas other authors describe an accumulation of M2-
like cells in the atherosclerotic plaque [61]. Although
the interpretation of these studies remains difficult in
the absence of single markers that can unequivocally
discriminate between macrophage subsets in vivo [15],
the macrophage phenotype in the synovial sublining
may reflect the same plasticity as in tumors, fat tissue,
and atherosclerosis.
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In contrast with the mixed phenotype of synovial sub-
lining macrophages, the intimal lining layer macro-
phages clearly displayed an MFIL-10-like phenotype. We
observed the same differences between the phenotype of
intimal lining layer and synovial sublining macrophages,
not only in SpA and RA but also in gout synovitis (data
not shown), suggesting that this macrophage distribu-
tion pattern is a global feature of synovial inflammation.
Together with the low expression of CD14 in the inti-
mal lining layer, this observation may fit a model
according to which the intimal lining layer contains
mainly mature resident macrophages, whereas the syno-
vial sublining is actively infiltrated with immature
monocyte-derived macrophages. This model is in agree-
ment with publications showing that the number of
synovial sublining but not intimal lining layer macro-
phages is associated with disease activity in RA and cor-
relates with response to therapy [7-9].
Concerning the differences between SpA and RA, this
model would predict that the synovial sublining is simi-
larly infiltrated by monocyte-derived macrophages with
a mixed phenotype in both pathologies. However, the
MRP8/14+ infiltrating macrophages were shown to accu-
mulate highly in the intimal lining layer in RA [3] and
secrete a variety of proinflammatory mediators [62]. In
contrast, the SpA intimal lining layer appears to consist
mainly of resident, MFIL-10-like macrophages, which is
in accordance with the lower levels of M1-derived cyto-
kines in SpA compared with RA synovial fluid [27] and
with the less-destructive appearance of SpA synovitis.
Based on these findings, modulating the polarization
and/or the migration of distinct macrophage subsets to
the intimal lining layer would represent interesting ther-
apeutic approaches for chronic synovitis.
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